Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
Recruiting · NCT06522256 · Interventional (participants receive a specific treatment) · Lead sponsor: ANRS, Emerging Infectious Diseases
View the official record on ClinicalTrials.gov →Interventions studied
High-resolution anoscopy
What this trial is about
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
- Informed and written signed consent
- Participant with regular health insurance
Exclusion criteria
- Participant under guardianship or curatorship
- Participant with free State medical assistance
- Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.
Where it is running
3 locations listed.
- Hôpital de la Croix Rousse - SMIT - Lyon, France
- Hôpital Saint-Louis - SMIT - Paris, France
- Hôpital Tenon - SMIT - Paris, France